Objectives: The Danish Myeloma Study Group initiated a randomized, placebo-controlled, double-blinded phase II study to investigate the efficacy of adding clarithromycin to cyclophosphamide-bortezomib-dexamethasone (VCD) induction therapy in transplant eligible, newly diagnosed multiple myeloma patients. The study was prematurely terminated due to severe complications, and no effect of adding clarithromycin was found. The aim of this study was to compare health-related quality of life (HRQoL) between the two groups and to explore the coherence hereof with adverse event (AE) registration by clinicians.
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Patient-experienced benefits and toxicities are valuable parameters for shared treatment decision-making in daily practice. [2] [3] [4] Also, PRO data results are important from a regulatory perspective in the evaluation of medicinal products, which has been stated by the US Food and Drug Administration (FDA) and European Medicine Agency (EMA) when new drugs or drug combinations are approved. 5, 6 Health-related quality of life during induction therapy and highdose chemotherapy with stem cell support (HDT) in newly diagnosed multiple myeloma (MM) patients has been reported in more studies. [7] [8] [9] [10] [11] In general, the patients report unchanged global quality of life (QoL) during induction therapy with clinically meaningful deterioration in global QoL, physical functioning and increased degree of pain and fatigue two weeks after HDT. Two months after HDT the patients report full recovery and further improvement until 12 months after HDT.
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The Danish Myeloma Study Group (DMSG) initiated a randomized, placebo-controlled double-blinded phase II study to investigate the efficacy and safety of adding clarithromycin to bortezomib-cyclophosfamide-dexamethason (VCD) induction therapy prior to HDT in newly diagnosed MM patients. 13 Clarithromycin in combination with lenalidomide and low-dose dexamethasone is been found to be an effective treatment regimen with manageable side effects in treatment naïve symptomatic MM patients. 14 The rationale for this study, entitled the CLAIM study, was to test these previous findings using a randomized placebo-controlled study design with addition of patient-reported HRQoL captured by validated PRO questionnaires.
In fact, a valid investigation of HRQoL during an anti-myeloma regimen with addition of clarithromycin has to our knowledge never been published.
The CLAIM study was prematurely terminated on 16 September 2016, after inclusion of 58 patients, due to a high incidence of serious adverse events (AE) in the intervention group. Response data did not suggest any effect of adding clarithromycin to the VCD regimen. 13 The primary objective of this analysis was to evaluate the patient-reported HRQoL in patients receiving clarithromycin added to the VCD induction therapy. The secondary objective was to compare patient-reported toxicities to AEs reported by clinicians.
| PATIENTS AND ME THODS

| Study design
Study details have been published previously. 13 Newly diagnosed transplant-eligible MM patients with treatment-demanding disease according to the International Myeloma Working Group criteria were eligible for inclusion. 15 The patients were randomized For evaluation of peripheral neuropathy, the "Functional Assessment of Cancer Therapy/Gynecologic Oncology Group Neurotoxicity" (FACT/GOG-ntx) subscale was used, which is a single domain 11-item questionnaire. 20 The questionnaire has been validated and used previously in myeloma patients for evaluation of treatment-related peripheral neuropathy. 21, 22 The domain was scored from 0 to 44 and a higher score means a lower degree of peripheral neuropathy.
| Health-related quality of life data collection procedure
The three questionnaires were scheduled to be completed by the patients at baseline (inclusion), before cyclophosphamide priming and two months after HDT. The patients were encouraged to complete the questionnaires electronically at home via a link sent by e-mail.
The Internet-based tool of Electronic Data Capture platform has been well accepted by haematological patients. 23 The email with a link was sent to patients at baseline, at day 60 and 180 after inclusion. If patients did not complete the questionnaire within 24 hr, a reminder was sent, and in case of non-response seven days after the target date, the link to the questionnaire was blocked. Patients, who
were not willing or able to answer the questionnaires electronically, completed the questionnaires by paper at study visits before cyclophosphamide priming and two months after HDT.
| Adverse events reported by clinicians
AEs were evaluated according to "Common Terminology Criteria of Adverse Events" (CTCAE) version 4.0 24 at day 1 of each VCD induction cycle, at study visits before cyclophosphamide priming and two months after HDT by clinicians. All unresolved AEs at the visit before cyclophosphamide priming were followed by the responsible clinician until the AEs were resolved.
| Statistical methods and handling of missing data
Calculation of domain scores and handling of missing items were performed as described in EORTC and FACT scoring manuals. 19, 25 For the analysis of the HRQoL mean scores results, mixed model for repeated measures with an unstructured covariance matrix was used. A baseline constrained model where baseline values are constrained to be equal across treatment groups was chosen. 26 Due to early study, termination sample size was lower than planned. Therefore, the HRQoL results were primarily interpreted by thresholds of clinical relevance between treatment groups.
27
A treatment group difference of ≥5 point was defined as clinically relevant for the EORTC domains and ≥11.8 points for the FACT/ GOG-ntx subscale. 28, 29 To explore the impact of non-responses to scheduled questionnaires, sensitivity analyses of the results of the global Q oL domain were performed using two methods (A and B). First, variables predicting non-responses were explored using odds ratio analyses. Spearman's correlation analysis was used to compare AEs assessed by clinicians with patient-reported toxicities. Cohen´s criteria for medium effect size was used to calculate the minimal important difference (MID) for the clinically meaningful change (0.5 × SD at baseline), and a score change above the MID was determined as clinical meaningful to the patient. 36 P-values below 0.05 were considered significant. R version 3.3.3
(R Foundation for Statistical Computing, Vienna, Austria) and SAS version 9.4 (SAS institute, Cary, NC, USA). SAS was used for mixed model for repeated measures, whereas R package "mice" was used for multiple imputations. Table 1 .
| RE SULTS
| Patient population and compliance
The completeness rates of questionnaires were 84% in the clarithromycin group and 89% in the placebo group. Mean scores at baseline and SD for each domain and treatment group are presented TA F I G U R E 2 (A-C) Graphs of the domains with a clinical relevant difference between the two treatment groups before cyclophosphamide priming. For physical, role and social functioning and insomnia and constipation the clinical relevant differences were persistent two months after HDT. For the functional domains including global health status/QoL,a higher score means better functioning/QoL, and for the symptom domains, a higher score means a higher degree of symptoms.
FuncƟonal domains -in favour of placebo Symptom domains -in favour of placebo Symptom domains -in favour of clarithromycin (A) (B) (C)
in Table 2 . The mean baseline scores in global QoL were imbalanced with a difference of 8.4 points between the two groups and a graph of change in global QoL score over time is presented in the supplementary file Figure S1 . The number of patients in the study at baseline, before cyclophosphamide priming and two months after HDT and the number of completed questionnaires are presented in the CONSORT diagram in Figure 1 . The main reason for early patient drop out was serious AEs, which was the case for four patients in the clarithromycin group and one patient in the placebo group.
Thirty-four patients (62%) completed the questionnaires electronically, and 21 patients (38%) chose paper questionnaires. Since some VCD induction cycles were postponed due to complications and some patients were treated with four cycles of VCD, not all patients completed the follow-up questionnaires at the scheduled time points before cyclophosphamide priming and two months after HDT. The follow-up questionnaires before cyclophosphamide priming were completed with a median of nine days too early (range −51 to 11) for the clarithromycin group and 12 days too early (range −41 to 1) for the placebo group. Also, the two months after HDT assessments were completed with a median of four days too early (range −36 to 45) for the clarithromycin group and one day too early (range −38 to 19) for the placebo group.
| Comparison of HRQoL between treatment groups
HRQoL domains with a clinical relevant difference in mean change of score before cyclophosphamide priming are presented in Figure 2 , 
| Adverse events registered by clinicians and patient-reported toxicities
In the correlation analysis, we compared clinician registered AEs to the patient-reported toxicities for the eight toxicity domains of fatigue, nausea and vomiting, dyspnoea, insomnia, appetite loss, constipation, diarrhoea and peripheral neuropathy. Since some discrepancies were observed between the time points of AE evaluation by clinicians at the study visits and the time points of answered questionnaires, time effect correlation analyses were carried out. For constipation, we observed a statistically significant time effect before cyclophosphamide priming (rho = −0.39; P = 0.012) and two months after HDT (rho = 0.47; P = 0.005). Also, for diarrhoea, there was a statistically significant time effect two months after HDT (rho = −0.34; P = 0.045). Therefore, correlation analyses were not performed for constipation at the two followup time points and for diarrhoea two months after HDT. Overall, poor correlations between the patient-reported toxicity and clinician registered AEs for all six toxicities were found with rho values <0.4 (Table 3 ).
| D ISCUSS I ON
Our data demonstrate that MM patients report a clinically relevant reduced HRQoL, when clarithromycin is added to the VCD regimen F I G U R E 3 Impact of non-responses to scheduled questionnaires. The analysis using mixed model repeated measure (solid lines), sensitivity analysis method A using multiple imputations (dotted lines) and sensitivity analysis methods B using missing score replacement with zero (spotted lines).
with persisting HRQoL sequelae two months after HDT. Using registered toxicities by CTCAE this knowledge could not be concluded from the clinicians' AE evaluation, since they underreported symptomatic toxicities.
A limitation of our results is that it is based on an underpowered study due to premature study termination with a poor questionnaire completion rate, which made us unable to obtain a valid statistical result. Still, when comparing our results to existing literature of HRQoL during induction therapy and HDT in MM patients, it is noteworthy that the patients in the clarithromycin group reported decreased HRQoL after induction phase. 7, 9 Our findings could be explained by the pharmacokinetics of bortezomib and clarithromycin. Bortezomib is primarily metabolized by the cytochrome P450 enzyme CYP3A4, which is known to be inhibited by clarithromycin. Thus, the reduced HRQoL could be a result of increased biological effect of bortezomib in the clarithromycin group. 13 Clarithromycin has been used in other treatment regimens for MM often in combination with lenalidomide and lowdose dexamethasone, which is found to have favourable toxicity profile.
14 This discrepancy in AE findings compared to our study supports the explanation of being caused by the pharmacokinetic interaction between bortezomib and clarithromycin, when those two drugs are administrated in parallel. In the CLAIM study, special precaution was made for the potential risk of QT prolongation, ventricular tachycardia and sudden death caused by clarithromycin. Severe cardiac disease or QT prolongation was exclusion criteria, and ECG was performed at screening, on day 4 and before start of VCD cycle 2. If the patient developed QT prolongation (QTc interval > 500 ms), the clarithromycin/placebo treatment was permanently discontinued. However, no serious cardiovascular events were reported during the study.
13
In clinical studies, AEs are traditionally collected as described in CTCAE guideline by clinicians. Still, we believe the results are convincing since clinicians may tend to underreport AEs.
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In this current study, we observed that there were non-responses to scheduled questionnaires, which is a common challenge in PRO data collection, analysis and interpretation. 32, 43, 44 The potential consequences of non-responses are decreased precision and power, and more seriously, the introduction of bias to the PRO data results, when a patient fails to complete a questionnaire because of severe illness or other reasons. It is recommended to design clinical studies with PRO data collection with focus on minimization of non-responses and to perform sensitivity analysis to explore the impact of non-responses on the PRO data results. 44, 45 In our study, more patients in the clarithromycin group dropped out early due to serious AEs resulting in a lower questionnaire completion compared to patients in the placebo group. Therefore, the analyses performed are hypothetically fragile for biased results. We performed analyses to explore the impact of non-responses of being "missing not at random". 46 We examined the mechanisms of non-responses and found that registration of a grade 3-4 AEs was a predictor of non-responses, which confirms that some of the non-responses were "missing not at random." When integrating this information into the sensitivity analysis method B, it was confirmed that non-responses to questionnaires do impact the results of the global QoL domain and that our results might be conservative. However, in the sensitivity analysis method A using multiple imputations, we found no impact of non-responses on the global QoL results. Limitations in using the multiple imputation method in our study are the low sample size and a limited number of patients with grade 3 or 4 AEs reporting a global QoL score. Also, the global QoL domain is described as a "distal" measure with limitations in interpretability due to greater mediation by personal and environmental characteristics rather than disease and treatment-related chances.
47
In conclusion, the CLAIM study demonstrated that adding clarithromycin to the VCD regimen in MM patients resulted in impaired HRQoL during the VCD induction phase continuing up to two months after HDT. The study emphasizes that well-designed randomized, collection is necessary to determine drug risk benefit assessment, and also to test well-known drugs in new combinations. Treatment org/0000-0001-7753-6768
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